We are live on ! Find out more
TTNP

Titan Pharmaceuticals
TTNP

Delisted

TTNP was delisted on the 1st of October, 2025.

Back to rankings

26 hedge funds and large institutions have $1.94M invested in Titan Pharmaceuticals in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

167% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

24% more funds holding

Funds holding: 21 → 26 (+5)

0% more ownership

Funds ownership: 0% → 0% (+0%)

27% less capital invested

Capital invested by funds: $2.65M → $1.94M (-$707K)

Holders
26
Holders Change
+5
Holders Change %
+23.81%
% of All Funds
0.59%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$1.15M
2
PCM
Perkins Capital Management
Minnesota
+$905K
3
AC
Armistice Capital
New York
+$166K
4
Renaissance Technologies
Renaissance Technologies
New York
+$43.5K
5
Vanguard Group
Vanguard Group
Pennsylvania
+$35.3K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$48K
2
WS
Wedbush Securities
California
-$22K
3
WPA
Winning Points Advisors
Florida
-$10.9K
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$3K
5
CIBC Private Wealth Group
CIBC Private Wealth Group
Georgia
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
CWM
1
Cornerstone Wealth Management
Missouri
$1M +$2.72K +1 New
SM
2
Sabby Management
Florida
$314K +$1.15M +422 New
PCM
3
Perkins Capital Management
Minnesota
$249K +$905K +333 New
Renaissance Technologies
4
Renaissance Technologies
New York
$146K +$43.5K +16 +9%
Vanguard Group
5
Vanguard Group
Pennsylvania
$90K +$35.3K +13 +12%
AC
6
Armistice Capital
New York
$46K +$166K +61 New
WPA
7
Winning Points Advisors
Florida
$25K -$10.9K -4 -11%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$19K – – –
Northern Trust
9
Northern Trust
Illinois
$11K – – –
Bank of America
10
Bank of America
North Carolina
$8K – – –
VF
11
Virtu Financial
New York
$8K +$27.2K +10 New
California Public Employees Retirement System
12
California Public Employees Retirement System
California
$6K – – –
Bank of New York Mellon
13
Bank of New York Mellon
New York
$3K – – –
BlackRock
14
BlackRock
New York
$2K – – –
CCB
15
Cutter & Co Brokerage
Missouri
$2K – – –
WAM
16
Wealthspire Advisors (Maryland)
Maryland
$2K – – –
Commonwealth Equity Services
17
Commonwealth Equity Services
Massachusetts
$2K +$10.9K +4 New
BCM
18
Blume Capital Management
California
$1K – – –
HNB
19
Huntington National Bank
Ohio
$1K – – –
Morgan Stanley
20
Morgan Stanley
New York
$1K – – –
BA
21
Ballew Advisors
Mississippi
$1K +$2.72K +1 New
UBS Group
22
UBS Group
Switzerland
$1K +$2.72K +1 New
APA
23
American Portfolios Advisors
New York
$565 – – –
WIM
24
Westside Investment Management
California
$491 – – –
Millennium Management
25
Millennium Management
New York
– -$48K -12 Closed
1
2

TTNP Hedge Fund Activity: Q3 2018 in Review

26 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Titan Pharmaceuticals (TTNP) for Q3 2018, worth a combined $1.94M — down 27% from $2.65M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TTNP positions and 3 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Sabby Management, opening a new position worth an estimated $1.15M. The largest seller was Millennium Management, exiting entirely with an estimated $48K sold.

  • 26 institutional investors held Titan Pharmaceuticals (TTNP) as of Q3 2018, up from 21 in Q2 2018.
  • Funds reported $1.94M of Titan Pharmaceuticals stock for Q3 2018, down 27% quarter-over-quarter.
  • 8 funds opened new Titan Pharmaceuticals positions in Q3 2018 and 3 closed out, a net change of +5 holders.
  • The largest Titan Pharmaceuticals buyer in Q3 2018 was Sabby Management, an estimated $1.15M added.
  • The largest Titan Pharmaceuticals seller in Q3 2018 was Millennium Management, an estimated $48K sold.

Based on aggregated 13F filings for Q3 2018.